DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes mark

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

Deutsche Bank analyst Kieran Ryan initiates coverage on DexCom (NASDAQ:DXCM) with a Buy rating an

FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time G

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raise

https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

DexCom CONNECT trial found G7 reduced A1C and improved glucose control in Type 2 diabetes patients n

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care

Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ

CONNECT study will demonstrate Dexcom CGM benefits for adults with Type 2 diabetes not using insulin

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

Through ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and lowers t

B of A Securities analyst Travis Steed maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the p

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and lowers the pri

DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexco

DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share B

Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Dat

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price t

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price t

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and lowers the pri

2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Ad

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.56 per share which beat the analyst consensus

MiniMed shows improved pipeline and valuation upside as insulin pump adoption grows despite rising c

GlucoTrack targets a Q2 2026 FDA IDE filing for CGM, backed by clinical data, manufacturing strategy

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers

Truist Securities analyst Richard Newitter reiterates DexCom (NASDAQ:DXCM) with a Buy and lowers

After Thursday's broad-based tech selloff, Wall Street staged a rebound as a softer-than-expecte

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and raises the pri

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and lowers t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Here's a look at the Q4 earnings report from DexCom.

DexCom (NASDAQ:DXCM) affirms FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.160 billi

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.68 per share which beat the analyst consensus